TickerFacts.

Zeo ScientifiX, Inc. (ZEOX): R&D Expense

Annual figures by period end, from SEC filings.

$100.0K
Year ended 2025-10-31
$102.0K
Trailing 12 months to 2026-04-30
-49.8%
3-year compound annual growth
-15.6%
5-year compound annual growth
$1.12M2019-10-31: $54.9K2020-10-31: $233.5K2021-10-31: $1.12M2022-10-31: $791.3K2023-10-31: $922.7K2024-10-31: $164.0K2025-10-31: $100.0K$100.0K
2019-10-31 R&D Expense (USD) 2025-10-31
Period endedR&D ExpenseChange YoYSource filing
2025-10-31$100.0K-39.0%2026-01-29, From 2024-11-01
2024-10-31$164.0K-82.2%2026-01-29, From 2023-11-01
2023-10-31$922.7K+16.6%2024-01-29, From 2022-11-01
2022-10-31$791.3K-29.4%2024-01-29, From 2021-11-01
2021-10-31$1.12M+379.6%2023-02-14, From 2020-11-01
2020-10-31$233.5K+325.7%2022-02-14, From 2019-11-01
2019-10-31$54.9Kn/a2021-02-08, From 2018-11-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$100.0K-39.0%
DBV Technologies S.A. (DBVT)2025-12-31$116.68M+30.6%
Prime Medicine, Inc. (PRME)2025-12-31$160.64M+3.4%
Ocugen, Inc. (OCGN)2025-12-31$39.75M+23.7%
Fate Therapeutics Inc (FATE)2025-12-31$107.83M-20.1%
CG Oncology, Inc. (CGON)2025-12-31$116.64M+42.1%
CRISPR Therapeutics AG (CRSP)2025-12-31$284.81M-8.2%
Surrozen, Inc. (SRZN)2025-12-31$29.36M+39.0%
Dyadic International Inc (DYAI)2025-12-31$2.15M+5.4%

Compare ZEOX, DBVT, PRME, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗